Antibodies, Monoclonal, Humanized
"Antibodies, Monoclonal, Humanized" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
| Descriptor ID |
D061067
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060 D12.776.124.790.651.114.224.060 D12.776.377.715.548.114.224.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal, Humanized".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal, Humanized".
This graph shows the total number of publications written about "Antibodies, Monoclonal, Humanized" by people in this website by year, and whether "Antibodies, Monoclonal, Humanized" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 9 | 9 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 7 | 7 |
| 2008 | 0 | 15 | 15 |
| 2009 | 0 | 8 | 8 |
| 2010 | 0 | 13 | 13 |
| 2011 | 6 | 14 | 20 |
| 2012 | 8 | 7 | 15 |
| 2013 | 8 | 6 | 14 |
| 2014 | 15 | 9 | 24 |
| 2015 | 6 | 9 | 15 |
| 2016 | 4 | 13 | 17 |
| 2017 | 4 | 10 | 14 |
| 2018 | 8 | 7 | 15 |
| 2019 | 12 | 9 | 21 |
| 2020 | 14 | 15 | 29 |
| 2021 | 24 | 9 | 33 |
| 2022 | 9 | 13 | 22 |
| 2023 | 7 | 9 | 16 |
| 2024 | 23 | 17 | 40 |
| 2025 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal, Humanized" by people in Profiles.
-
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers. Haematologica. 2025 Mar 01; 110(3):706-714.
-
Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas. Blood Adv. 2025 Feb 25; 9(4):696-703.
-
Antitumor Activity and Biomarker Analysis for TROP2 Antibody-Drug Conjugate Datopotamab Deruxtecan in Patient-Derived Breast Cancer Xenograft Models. Clin Cancer Res. 2025 Feb 03; 31(3):573-587.
-
Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Feb 03; 31(3):529-542.
-
Phase I/II Study of the Aurora Kinase A Inhibitor Alisertib and Pembrolizumab in Refractory, Rb-Deficient Head and Neck Squamous Cell Carcinomas. Clin Cancer Res. 2025 Feb 03; 31(3):479-490.
-
Respiratory Syncytial Virus Disease Burden and Nirsevimab Effectiveness in Young Children From 2023-2024. JAMA Pediatr. 2025 Feb 01; 179(2):179-187.
-
Dupilumab for chronic obstructive pulmonary disease with type 2 inflammation: a pooled analysis of two phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2025 Mar; 13(3):234-243.
-
Integrating CTLA-4/PD-1 blockade into cervical cancer management: Results of COMPASSION-16. Med. 2025 Jan 10; 6(1):100558.
-
Concomitant antihistamine administration is associated with improved survival outcomes in patients with locally advanced or metastatic urothelial carcinoma treated with atezolizumab. Analysis of individual participant data from IMvigor210 and IMvigor211. Urol Oncol. 2025 Mar; 43(3):188.e9-188.e17.
-
Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial. Nat Med. 2025 Jan; 31(1):144-151.